{"id":"NCT01881230","sponsor":"Celgene","briefTitle":"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","officialTitle":"A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly NabÂ®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-09-26","primaryCompletion":"2016-10-28","completion":"2016-10-28","firstPosted":"2013-06-19","resultsPosted":"2018-03-08","lastUpdate":"2019-02-21"},"enrollment":191,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Tumor","Breast Cancer","Cancer of the Breast","Estrogen Receptor- Negative Breast Cancer","HER2- Negative Breast Cancer","Progesterone Receptor- Negative Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer","Triple-negative Breast Cancer","Triple-negative Metastatic Breast Cancer","Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"nab-Paclitaxel","otherNames":["Abraxane"]},{"type":"DRUG","name":"Carboplatin","otherNames":["Paraplatin,","Paraplatin AQ"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]}],"arms":[{"label":"nab-Paclitaxel plus Gemcitabine","type":"EXPERIMENTAL"},{"label":"nab-Paclitaxel plus Carboplatin","type":"EXPERIMENTAL"},{"label":"Gemcitabine plus Carboplatin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.","primaryOutcome":{"measure":"Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.","timeFrame":"From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C","effectByArm":[{"arm":"Arm A: Nab-Paclitaxel + Gemcitabine","deltaMin":5.5,"sd":null},{"arm":"Arm B: Nab-Paclitaxel + Carboplatin","deltaMin":8.3,"sd":null},{"arm":"Arm C: Gemcitabine + Carboplatin","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0183"},{"comp":"OG001 vs OG002","p":"0.0152"},{"comp":"OG000 vs OG002","p":"0.8599"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Australia","Austria","Brazil","Canada","France","Germany","Greece","Italy","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["26673577","31849532"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":60},"commonTop":["Neutropenia","Fatigue","Anaemia","Nausea","Constipation"]}}